Helsinki’s Nanoform is converting nanoparticle engineering into clinic-ready products. Its Controlled Expansion of Supercritical Solutions (CESS®) process creates crystalline API nanoparticles down to tens of nanometres using supercritical CO₂, avoiding carriers and hydrocarbon solvents and boosting dissolution and bioavailability.
In 2025 Nanoform pushed several milestones:
- pivotal human bioequivalence trials for a single 160 mg nano-tablet enzalutamide intended to replace four 40 mg tablets.
- a €5 million R&D loan from Business Finland to support clinical work on nanoapalutamide.
- in April 2025, the Bio R&D team achieved a 10x scale-up of their Biologics technology, by producing 2kg in one continuous run on the pilot GMP line.
Independent sources (Pharmafile, PharmTech, Manufacturing Chemist) corroborate technical claims: peer-reviewed analyses and conference posters document CESS performance and in-line characterisation; industry coverage in Pharmafile, PharmTech and Manufacturing Chemist reports Business Finland funding, AstraZeneca evaluations and the Celanese partnership on long-acting implants. Analyst notes and market data show growing commercial interest and listed coverage.
Nanoform now blends fee-for-service nanoforming with creation of proprietary product kernels, reformulated APIs ready for licensing. This hybrid model, supported by clinical trials, peer-reviewed publications and analyst reports, aims to cut pill burden, improve adherence and unlock new formulation routes, shifting value from service margins to asset-led pharma partnerships. In parallel with clinical and strategic progress, regulatory inspections and upcoming pivotal readouts will determine commercial uptake and licensing timelines across markets.
Highlights
- CESS® produces crystalline API nanoparticles (tens of nm) using supercritical CO₂.
- 2025 pivotal bioequivalence trials for nano-enzalutamide (single 160 mg tablet).
- €5M R&D loan from Business Finland to advance nanoapalutamide.
- Collaborations: Celanese (long-acting implants), technology evaluations with major pharma.
- Analyst coverage and market data show investor and commercial interest.
- Strategic shift from services toward licensable product kernels (APIs designed for licensing).
- Going from pills to subcutaneous injections and inhaled delivery.
Nanoform uses CESS® nanoparticle engineering to shrink pill burden and build licensable drug-enabling assets, with 2025 clinical and scale-up milestones vetted by independent sources.
Photo: Nanoform
